Ken Griffin Haemonetics Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$72.45 - $91.58 $912,870 - $1.15 Million	12,600 Added 53.62%	36,100 $2.9 Million
Q2 2024 Aug 14, 2024	SELL	$81.24 - $97.37 $227,472 - $272,636	-2,800 Reduced 10.65%	23,500 $1.94 Million
Q1 2024 May 15, 2024	BUY	$71.24 - $85.35 $762,268 - $913,244	10,700 Added 68.59%	26,300 $2.24 Million
Q4 2023 Feb 14, 2024	SELL	$80.59 - $92.61 $604,425 - $694,575	-7,500 Reduced 32.47%	15,600 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$82.56 - $93.49 $726,528 - $822,712	8,800 Added 61.54%	23,100 $2.07 Million
Q2 2023 Aug 14, 2023	SELL	$80.84 - $89.45 $331,444 - $366,745	-4,100 Reduced 22.28%	14,300 $1.22 Million
Q1 2023 May 15, 2023	BUY	$72.75 - $90.6 $894,825 - $1.11 Million	12,300 Added 201.64%	18,400 $1.52 Million
Q4 2022 Feb 14, 2023	SELL	$73.85 - $86.14 $553,875 - $646,050	-7,500 Reduced 55.15%	6,100 $479,000
Q3 2022 Nov 14, 2022	BUY	$63.3 - $78.66 $101,280 - $125,856	1,600 Added 13.33%	13,600 $1.01 Million

332

53.8M

689K

345K

Ticker HAE
Exchange NYSE
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 51,316,500
Market Cap $3.97B
Description
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous s...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.